Valuate Health Consultancy

In the latest issue of Market Access Musings, Ricardo Paredes from Entrée Health shares five ways to make market access strategies more inclusive and effective. #marketaccess #pharma #biotech #inclusivedesign

In the latest issue of Market Access Musings, Elisa Remoundos of Entrée Health discusses why brand planning is the perfect opportunity to incorporate social determinants of health. #marketaccess #sdoh #pharma #biotech #healthequity

In the latest issue of Market Access Musings: #Asembia24 highlights from Day One, message testing for #pharma and #marketaccess, and more:

NEW EPISODE OF THE IDI PODCAST: Listen to Alex Goldstein Mindlin discuss message testing for #pharma and #marketaccess 👇 👇 👇 On Apple Podcasts: https://lnkd.in/eeybFVeW On Spotify: https://lnkd.in/eTX27b62

Day 1.5 update from #Asembia24: A lot of compelling words and phrases being used to describe the state of our healthcare system today - standouts include “chaotic change,” “uncertainty,” and.. “crisis.” At the same time there is a lot of hope that this era of tumult will give rise to incredible innovations, of which we’re already starting to see signs of through successful case studies of alternative payment and contracting models, integration of digital solutions and AI (not just a buzzword!), and execution of value-based models that are bringing the focus back to clinical outcomes (particularly evidenced by the exciting collaboration between Takeda and Optum). Looking forward to learning more about all of the above! Valuate Health Consultancy

Kimberly Tsai, PharmD has a report from Day 1 of #Asembia24:

Nuggets from day 1 of #Asembia2024! A lot of pulled threads from AMCP Annual, as well as some new learnings to help paint the fuller picture: Key trends to monitor in the CGT and rare disease space: - The booming category of self-insured employers (the TPA/stop-loss market is projected to grow to $800 billion by 2030) - SPs taking on restrictive management tactics (79% of SPs are reported to be using an NDA block) - Increased awareness that patient eligibility is expanding among CGT and rare disease products – rare disease is not so rare anymore - Expect new demand for more holistic care (think clinical management on top of bread-and-butter distribution and access services) to produce greater value that matches these complex patient journeys As far as the IRA goes.. While many aspects of program rollout (namely, drug price negotiation and Part D benefit redesign) remain uncertain, hard data is starting to emerge that provides some certainty to the unintended consequences we’ve been speculating about over the past year: - Most payers are planning to react to higher financial liability through mechanisms like narrower formularies (73%), increase in utilization for specialty products (93%) and negotiating for higher rebate (75%)* - While OOP smoothing via the Medicare Prescription Payment Plan will benefit many Part D beneficiaries, a significant proportion will still be left in the dust – such as the 75% of Medicare beneficiaries that have difficulty paying $2,000 to begin with, and the 77% that do not know about the OOP cap (especially problematic for an opt-in program) - As far as the Part D benefit redesign goes, manufacturers play a key role in raising awareness and proactivity among patients and providers to help drive greater participation *Presented as part of a series of data from Xcenda’s “Managed Care Network Survey,” to be officially unveiled in the coming months. Valuate Health Consultancy

Walgreens Boots Alliance saying all the right things about increasing patient access to cell & gene therapy in their announcement of a dedicated service center. Wondering whether it will do that... or will it be another hurdle in an already long & winding access journey? #AXS24 #specialtypharmacy #AMAWA Entrée Health Valuate Health Consultancy Archbow Consulting

Already hitting the floor at #Asembia24 with team members Betsy Appelsies, MBA and Jamie Reyes Let’s connect!

Have you ever wondered what a #SpecialtyPharmacy does and what services they offer? In our newest #AsktheExperts series, Kristy Frizzo explains how Archbow can help with SP 101 #training support for #pharma manufacturers. Contact us at info@archbow.com for more information. #biotech